Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Inv. presentation
Outlook Therapeutics, Inc. (ONS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/25/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/14/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones · Prescription Drug User Fee Act goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration ISELIN, N.J., August 14, 2023 — Outlook Therapeutics, Inc. , a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of wet AMD, today announced recent corporate highlights and financial results for its fiscal third quarter ended June 30, 2023. Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, commented, “We continue to be focused on our pre-launch activi..."
05/16/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/16/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
Docs: "Opinion of Cooley LLP",
"At-the-market-sales agreement between the Company and BTIG, LLC"
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/15/2023 8-K Quarterly results
Docs: "Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update ● Upcoming Prescription Drug User Fee Act goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration ● Pre-launch commercial activities continue in preparation for potential approval and launch of ONS-5010 ISELIN, N.J., May 15, 2023 – Outlook Therapeutics, Inc. , a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced recent corporate highlights and financial results for its fiscal second quarter ended March 31, 2023. “We continue to make sig..."
04/03/2023 8-K/A Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
02/14/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/14/2023 8-K Quarterly results
01/27/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
01/24/2023 10-K/A Annual Report for the period ended September 30, 2022 [amend]
01/06/2023 D Form D - Notice of Exempt Offering of Securities:
01/06/2023 D Form D - Notice of Exempt Offering of Securities:
12/29/2022 10-K Annual Report for the period ended September 30, 2022
12/29/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
12/29/2022 8-K Quarterly results
12/23/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Form of Warrant",
"Opinion of Cooley LLP",
"Form of Securities Purchase Agreement, by and between the Company and the Purchasers",
"Letter Agreement, by and between the Company and M.S. Howells & Co",
"Outlook Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules"
12/23/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
12/22/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Exhibit E",
"EXHIBIT A",
"Outlook Therapeutics® Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD · Decision for potential approval expected from European Commission in early 2024 · Submission follows the U.S. FDA acceptance of the ONS-5010 BLA for wet AMD, with a PDUFA date of August 29, 2023 ISELIN, N.J., December 22, 2022 — Outlook Therapeutics, Inc. , a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the validation of its Marketing Authorization Application by the European Medicines Agency for ONS-5010 / LYTENAVA™ , an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related ..."
11/23/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
08/10/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/10/2022 8-K Quarterly results
07/07/2022 SC 13D/A Tenshi Healthcare Pte. Ltd. reports a 10.2% stake in Outlook Therapeutics, Inc.
07/07/2022 SC 13D GMS Ventures & Investments reports a 25.1% stake in Outlook Therapeutics, Inc.
06/17/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/17/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
05/31/2022 8-K Quarterly results
05/13/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/13/2022 8-K Quarterly results
04/22/2022 SC 13D/A Tenshi Healthcare Pte. Ltd. reports a 25.6% stake in Outlook Therapeutics, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy